Primaa provides AI-based software for pathologists to detect cancer biomarkers and analyze medical images efficiently.
Primaa has raised $8.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2025.
Primaa's investors include Swen Capital Partners, Elaia, Super Capital VC, Malakoff Humanis.
Primaa is headquartered in Paris, France.
Primaa provides AI-based software for pathologists to detect cancer biomarkers and analyze medical images efficiently.
Primaa is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Primaa — Funding & Investors." VCBacked, October 29, 2025, https://www.vcbacked.co/company/primaa. Accessed August 14, 2026.
VCBacked. (2025). Primaa — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/primaa
{{cite web |title=Primaa — Funding & Investors |url=https://www.vcbacked.co/company/primaa |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated